Other research analysts also recently issued research reports about the company. Brookline Capital Acquisition reduced their price objective on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Brookline Capital Management reduced their price objective on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th.
Shares of BLPH stock opened at $1.00 on Monday. The business’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $2.20. Bellerophon Therapeutics has a one year low of $0.67 and a one year high of $5.95. The stock has a market capitalization of $9.55 million, a PE ratio of -0.53 and a beta of -0.15.
An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 24,134 shares of the biotechnology company’s stock, valued at approximately $75,000. Millennium Management LLC owned 0.25% of Bellerophon Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 12.93% of the company’s stock.
Bellerophon Therapeutics Company Profile (Get Rating)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- MarketBeat: Week in Review 5/30 – 6/3
- Dividend Capture Strategy: What You Need to Know
- Xiaomi Co: Facing Macro Headwinds
- Okta On Verge Of Multi-Week Rally
- Don’t Bet On A Bounce For RH
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.